Genomic interventions may improve disease-risk stratification and patient-tailored treatment. At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, outlines the processes and challenges surrounding the health economic evaluation of genomic technologies in Europe. Clinical trials, such as the prospective validation of a 21-gene expression assay in breast cancer (Trial Assigning IndividuaLized Options for Treatment, TAILORx), are providing the data necessary to define the clinical utility of genomic profiling tests.
This content is supported by Genomic Health, Inc.
